Researchers with the University of Cincinnati and Johns Hopkins Medicine developed a potential treatment for brain cancer that uses nanofibers embedded with a combination of drugs that work in concert to target tumors.

The drugs proved more effective in combination than when administered alone and can provide both immediate and long-lasting doses to kill cancer cells.

Lead author Daewoo Han, an assistant professor in UC’s College of Engineering and Applied Science, and UC Distinguished Research Professor Andrew Steckl incorporated the drugs into electrospun fiber membranes, creating a nanofiber drug delivery system. Steckl’s NanoLab at the University of Cincinnati is a leading developer of this technology that uses an electric field to create a multilayered fiber mesh for drug delivery, among other uses.

“This combination is pretty powerful,” Steckl said.

Glioblastoma is the most common and aggressive form of brain cancer in adults. Researchers at UC and Johns Hopkins found that the three federally approved drugs used to treat glioblastoma (temozolomide, acriflavine and PT2385) work better in combination than they would alone, a pharmaceutical phenomenon called synergism.

“When you add them together, three things can happen,” Steckl said. “The combination is negative; the effect is additive, like one plus one equals two; or it’s synergistic, which is like one plus one equals three.”

The study was published in the journal ACS Biomaterials Science & Engineering. The research was supported with a grant from the National Institutes of Health.

Steckl said glioblastoma is extremely difficult to treat because its heterogeneous cells allow for mutations that help the cancer evade treatment.

“It’s tough to control,” Steckl said. “It comes in through the window and when you close the window, it comes through the door. And when you close that, it comes through the chimney.”

Glioblastoma also has high recurrence. And the blood-brain barrier limits the effectiveness of other traditional chemotherapies.

“Our NanoMesh system was designed to solve these issues by enabling localized long-term delivery of multiple synergistic drugs directly at the tumor site after surgery,” UC’s Han said.

UC researchers worked with a team at Johns Hopkins Medicine, including Betty Tyler, a professor of neurosurgery, and postdoctoral researcher Hasan Slika. Tyler said researchers are looking to attack the disease with combinations of therapies.

“Unfortunately, cancers know how to pivot to evade therapeutic treatment,” she said. “So we’re approaching treatment multidimensionally.”

Tyler has helped develop other cutting-edge therapies now commonly used to treat cancer.

“Current therapies have increased patient survival and given them more birthdays,” she said. “But we’re still working on improving options.”

In animal trials, all untreated mice with glioblastoma died within 19 days. But a majority of mice treated with the three-layer nanofiber mesh survived twice as long. And 40% survived past the 120-day conclusion of the experiment in a plateau that stretched for more than 80 days.

Han said using electrospun fiber mesh, doctors can precisely control the dosage and release and the implant geometry, which contribute to its effectiveness. And just as the blood-brain barrier protects the brain from toxins, the barrier also protects the body from the toxic side effects of the medicine applied to the brain, Han said.

UC researchers are now working on optimizing the long-term release of medicines using advanced nanofiber structures. And the delivery system has broad potential in applications for other difficult-to-treat diseases, Han said.

“What’s next will be very exciting,” Han said. “Our ultimate goal is moving forward to a clinically translatable system that improves both survival and quality of life for patients with difficult-to-treat cancers, including glioblastoma.”

Journal

ACS Biomaterials Science & Engineering

Funder

NIH/National Institutes of Health

DOI

10.1021/acsbiomaterials.5c01482

bu içeriği en az 2000 kelime olacak şekilde ve alt başlıklar ve madde içermiyecek şekilde ünlü bir science magazine için İngilizce olarak yeniden yaz. Teknik açıklamalar içersin ve viral olacak şekilde İngilizce yaz. Haber dışında başka bir şey içermesin. Haber içerisinde en az 12 paragraf ve her bir paragrafta da en az 50 kelime olsun. Cevapta sadece haber olsun. Ayrıca haberi yazdıktan sonra içerikten yararlanarak aşağıdaki başlıkların bilgisi var ise haberin altında doldur. Eğer yoksa bilgisi ilgili kısmı yazma.:
Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits:

Keywords

Gliomas represent the most prevalent form of malignant brain tumors among adults, frequently associated with dismal prognoses, especially in aggressive forms like glioblastoma multiforme (GBM). The heterogeneity of gliomas demands refined biomarkers to aid diagnosis, prognosis, and therapeutic strategies. This context prompted Marlene Happe and colleagues to dissect the expression patterns of LRIG protein members and interpret their relevance in tumor biology. Their findings illuminate the potential tumor-suppressive role of LRIG1 and its declining expression correlating with advancing malignancy, offering promising avenues for targeted therapies.

Crucially, the team demonstrated that LRIG1 protein levels are markedly reduced in higher-grade gliomas when compared to control and low-grade tumor tissues. Low-grade gliomas exhibited substantially higher LRIG1 expression, whereas high-grade tumors—particularly primary GBMs—showed the lowest protein abundance. Such gradation in LRIG1 suggests its function as a brake against tumor aggressiveness, where diminishing levels might facilitate unchecked cellular proliferation. Remarkably, secondary GBMs, which evolve from lower-grade gliomas, maintained relatively higher LRIG1 expression than primary GBMs, potentially contributing to variations in clinical outcomes between these tumor subsets.

Mechanistically, LRIG1 is implicated in negative regulation of receptor tyrosine kinases, pivotal modulators of cellular proliferation and survival signaling cascades. Its reduced expression in advanced gliomas may lead to hyperactive growth factor pathways, exacerbating malignancy. Western blotting and PCR analyses conducted by the researchers confirmed the inverse relationship between LRIG1 levels and tumor grade at both protein and mRNA transcriptional levels, underscoring a consistent pattern of downregulation as tumors become more hostile.

In stark contrast, LRIG2 displayed a more intricate expression profile. While gene expression data indicated higher LRIG2 mRNA levels in lower-grade gliomas, the corresponding protein levels paradoxically increased in more malignant tumors. This discordance between transcript and protein abundance hints at complex post-transcriptional or post-translational regulatory mechanisms modulating LRIG2 protein synthesis or stability. Understanding these layers of regulation is critical, as LRIG2 has been suspected to facilitate tumor progression, in opposition to the suppressive function of LRIG1, revealing heterogeneous roles within the LRIG family.

LRIG3 expression patterns add another layer of complexity. The protein was found to be upregulated in glioma tissues compared to normal brain tissue, with the highest levels detected in low-grade tumors. Intriguingly, LRIG3 expression did not significantly fluctuate with chemotherapy, suggesting resistance to treatment-induced modulation or a stable expression profile irrespective of therapy. This stability across treatment regimens may impact its utility as a biomarker or therapeutic target and requires additional study to elucidate LRIG3’s function in glioma biology.

The comprehensive analysis of these three LRIG family members by Happe et al. emphasizes their differential expression as critical molecular signatures distinguishing glioma grades. By integrating protein quantification and mRNA transcript evaluations, the study offers robust evidence for the inverse association of LRIG1 with glioma severity and reveals the nuanced, potentially dichotomous roles of LRIG2 and LRIG3. Such findings advocate for expanding LRIG-focused research, which could revolutionize glioma diagnostics and therapeutics through biomarker development or targeted molecular interventions.

Furthermore, the dissociation observed between LRIG2 mRNA and protein levels suggests the involvement of regulatory mechanisms such as microRNA interference, alternative splicing, or proteasomal degradation selectively impacting protein abundance. Deciphering these regulatory layers could unveil novel therapeutic vulnerabilities in glioma cells that exploit the unique expression dynamics of LRIG proteins. The study also highlights the importance of correlating transcriptomic data with proteomic outcomes to garner a comprehensive understanding of tumor biology.

Despite the significance of the LRIG proteins in glioma pathology, the study notes that chemotherapy had limited impact on their expression profiles. This observation suggests that conventional therapies may not exert pressure on these molecular targets or that tumor cells maintain LRIG levels through compensatory mechanisms. Such resistance highlights the need for alternative strategies that directly modulate LRIG activity or expression to restrain tumor progression.

Notably, by stratifying gliomas according to WHO grades and tumor subtype—primary versus secondary GBMs—the researchers provide a nuanced view of the molecular heterogeneity within these tumors. This stratification is vital for tailoring precision medicine approaches, potentially allowing clinicians to use LRIG1 expression levels as a prognostic indicator or to select patients likely to benefit from LRIG-targeted therapies.

The study’s findings also open intriguing questions about the functional interplay between the LRIG family proteins. The tumor-suppressive actions of LRIG1 and LRIG3 contrasted with the tumor-promoting tendencies of LRIG2 point toward a finely tuned regulatory network balancing growth signaling in glioma cells. Untangling these interrelationships could yield insights into glioma pathogenesis and pinpoint combination strategies for simultaneous modulation of multiple LRIG proteins.

In summary, this investigation elevates the LRIG proteins—especially LRIG1—to prominence as vital molecular markers with therapeutic potential in glioma management. The strong negative correlation between LRIG1 protein levels and tumor grade underscores its candidacy as a biomarker to improve diagnostic accuracy and refine prognostication. Moreover, the differential expression profiles of LRIG2 and LRIG3 invite further functional and mechanistic studies to fully exploit the LRIG family in combating malignant gliomas.

With gliomas remaining formidable challenges in neuro-oncology, this research charts a promising path forward. It paves the way for developing LRIG-targeted diagnostic assays and therapeutic agents, potentially improving outcomes for patients afflicted with these devastating brain tumors. As investigations continue, elucidating the roles and regulation of LRIG proteins may transform the clinical landscape of glioma treatment and enhance personalized care in this critical field.

Subject of Research: Not applicable

Article Title: LRIG1-3 in gliomas: LRIG1 protein expression decreased in higher grade gliomas

News Publication Date: 6-Nov-2025

Web References: http://dx.doi.org/10.18632/oncotarget.28775

Image Credits: Copyright © 2025 Happe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), allowing unrestricted use, distribution, and reproduction in any medium with credit to the original authors.

Keywords: cancer, oncology, glioma, glioblastoma, LRIG1, LRIG2, LRIG3

The investigation centered on four pivotal immune checkpoint genes—CD276, CD40, TNFSF14, and TNFSF9—and their role in glioblastoma progression, specifically within the context of cuproptosis. Utilizing transcriptional data acquired from The Cancer Genome Atlas (TCGA), the team employed LASSO Cox regression analysis to pinpoint these genes as key factors linked with copper-dependent cytotoxicity in GBM. Their findings not only deepen the molecular understanding of glioma biology but also highlight the prognostic significance of these genes, potentially guiding therapeutic stratifications.

Cuproptosis represents a recently characterized form of programmed cell death triggered by intracellular copper accumulation leading to toxic protein aggregation. The study delves into this intricacy by investigating the copper death-related protein FDX1, establishing its correlation with immune checkpoint expression. This approach innovatively links metabolic and immune regulatory pathways, reminding us that glioblastoma’s resistance mechanisms may not solely rely on the tumor’s microenvironment or genetic mutations but also on nuanced metal ion homeostasis.

Expression analyses revealed that CD276, CD40, and TNFSF14 were significantly upregulated in GBM tissues compared to adjacent normal brain tissues, indicating their potential roles as oncogenic drivers. Contrastingly, TNFSF9 showed marked downregulation. This differential expression pattern delineates a complex immune checkpoint milieu in the glioma microenvironment, which may influence tumor immune evasion and responsiveness to therapies that modulate the immune system.

The prognostic implications of these findings are profound. Patients exhibiting elevated levels of CD276, CD40, and TNFSF14 demonstrated significantly poorer survival outcomes. This indicates that these immune checkpoint molecules may contribute to an immunosuppressive tumor microenvironment that facilitates glioblastoma aggressiveness. Intriguingly, TNFSF9 expression correlated inversely with prognosis, suggesting a potentially protective or tumor-suppressive role.

To translate these molecular insights into functional consequences, the study performed gene knockdown and overexpression experiments on glioma cell lines A172 and U251. Silencing CD276, CD40, and TNFSF14 notably suppressed tumor cell viability, reinforcing their potential as therapeutic targets. Conversely, overexpression of TNFSF9 curtailed cell growth, further supporting its unique negative correlation with glioma progression and indicating that enhancing TNFSF9 activity may form part of future treatment modalities.

The study’s combination of large-scale bioinformatic analyses with rigorous in vitro validation underlines the robustness of the findings. Moreover, the integration of cuproptosis into the paradigm of tumor biology opens new avenues for drug development, especially considering that copper chelators or agents modulating copper homeostasis could synergize with immune checkpoint inhibitors—arguably changing the treatment landscape for patients plagued by GBM.

Notably, the research identifies FDX1 as a key regulator that links copper-induced cytotoxicity with immune checkpoint regulation. The biological functions of FDX1 in electron transfer and mitochondrial metabolism are well-known, but this study pioneers its association with tumor immunity and cuproptosis, offering a promising molecular target that merits further investigation in preclinical and clinical settings.

Glioblastoma’s notorious resistance to traditional therapies such as temozolomide and radiotherapy necessitates innovative approaches. This study’s insights suggest that targeting the intersection of metabolic remodeling and immune evasion via cuproptosis-related immune checkpoints could bypass conventional treatment roadblocks by rendering glioma cells more susceptible to immune-mediated destruction.

As immune checkpoint blockade therapies continue to revolutionize cancer treatment, understanding their interplay with cellular death pathways is critical. This research exemplifies how such comprehensive molecular dissection informs precision medicine, enabling clinicians to foresee which patients might benefit from novel combinatorial regimens that incorporate copper modulation and immune checkpoint inhibition.

Furthermore, the observed dichotomous roles of immune checkpoints in GBM reported here underscore the complexity inherent to immune regulation within tumors. While CD276, CD40, and TNFSF14 seem tumor-promoting, the paradoxical behavior of TNFSF9 urges caution in therapeutic targeting, highlighting the need for context-dependent strategies that consider the multifaceted nature of tumor immunobiology.

The authors conclude that cuproptosis-related immune checkpoint expression is not only a biomarker for glioma prognosis but also a mechanistic gateway towards designing targeted immunotherapies. This approach could eventually surmount glioblastoma’s immunosuppressive microenvironment, which has long impeded effective immune engagement and durable therapeutic responses.

In sum, this pioneering investigation establishes a novel mechanistic link between copper-induced cell death and immune checkpoint pathways in glioblastoma, setting the stage for innovative treatments that combine metal ion biology and immuno-oncology. As research continues, these findings may pave the way for personalized therapeutic regimens offering renewed hope to patients battling this devastating malignancy.

Subject of Research: Molecular mechanisms linking immune checkpoint expression to cuproptosis in glioblastoma multiforme.

Article Title: Identification and validation of cuproptosis-related immune checkpoint expression for glioblastoma.

Article References: Huang, J., Tong, S., Liu, J. et al. Identification and validation of cuproptosis-related immune checkpoint expression for glioblastoma. BMC Cancer 25, 1723 (2025). https://doi.org/10.1186/s12885-025-15195-5

Image Credits: Scienmag.com

DOI: 06 November 2025

Keywords: glioblastoma, cuproptosis, immune checkpoints, CD276, CD40, TNFSF14, TNFSF9, FDX1, copper-induced cell death, immunotherapy, tumor microenvironment, LASSO Cox regression, prognostic biomarkers

Glycosylation, a post-translational modification where sugar molecules attach to proteins, plays a pivotal role in diverse biological processes, such as cell signaling, immune response, and tumor development. The heterogeneity of glycosylation within tumors, particularly in glioblastoma, has long posed challenges for effective treatment and diagnosis. Hu and colleagues’ integrated approach employs state-of-the-art mass spectrometry techniques to analyze the intricacies of N-glycosylation, providing a comprehensive view of its role in glioblastoma pathophysiology.

This study emphasizes the importance of characterizing the N-glycoproteome in cancer research, particularly in glioblastoma, where glycosylation patterns can reflect tumor aggressiveness and prognostic outcomes. Through meticulous experimental design, the researchers investigated various GBM samples, focusing on the variations in N-glycosylation and their potential implications for treatment response. By employing both proteomics and glycoproteomics, they successfully highlighted significant heterogeneities in glycosylation profiles, which could lead to stratified treatment approaches for GBM patients.

The alterations in sialylation and fucosylation were particularly striking, revealing their potential role in immune evasion and tumor progression. Sialic acids are well-known for their ability to modulate cell interactions and shield cells from immune detection. The study’s findings suggest that increased sialylation in glioblastoma may contribute to the tumor’s evasive maneuvers against the host immune system, complicating therapeutic interventions. Furthermore, fucosylation modifications were shown to correlate with aggressive cancer phenotypes, pointing towards a critical area for potential therapeutic targeting.

Understanding the dynamics of these sugar modifications offers a new dimension to the conventional approaches that primarily focus on protein expression alone. With this integrated proteomic and glycoproteomic characterization, researchers can now begin to see a more comprehensive landscape of GBM biology. This dual approach not only elucidates the functional impact of glycosylation but also reveals potential biomarkers that could be exploited for therapeutic purposes.

The implications of these findings could revolutionize the landscape of glioblastoma treatment. By targeting specific glycosylation pathways, there may be opportunities to develop novel inhibitors that disrupt the tumor’s ability to evade immune responses, thereby enhancing the effectiveness of existing therapies. Moreover, the heterogeneities observed in glycosylation patterns may serve as a basis for personalized medicine, allowing clinicians to tailor treatment strategies to individual patient profiles.

In the intricacies of glioblastoma treatment, the need for detailed molecular characterization cannot be overstated. As the researchers have shown, variations in cancer glycoproteins could inform both diagnosis and treatment strategies. Such insights underscore the necessity for ongoing research into the molecular underpinnings of GBM and other malignancies, which may ultimately lead to more effective interventions and improved patient outcomes.

As the battle against glioblastoma continues, this study stands as a testament to the power of interdisciplinary research. By combining proteomics and glycoproteomics, the authors not only expand the horizons of cancer biology but also exemplify the potential for future breakthroughs stemming from such integrative approaches. The findings of Hu et al. offer a hopeful glimpse into a future where the complex interplay of proteins and glycan structures is harnessed for better clinical outcomes.

Moving forward, these insights will need to be further validated in extensive clinical trials to assess their potential in real-world applications. The path from bench to bedside remains complex, yet the groundwork laid by this research is invaluable. It provides not only a deeper understanding of glioblastoma biology but also highlights the critical importance of glycosylation in cancer diagnostics and therapeutics.

In conclusion, the integration of proteomics and glycoproteomics presents a powerful tool for unraveling the complexities of glioblastoma multiforme. By characterizing the unique glycosylation patterns and their biological implications, researchers are taking significant strides toward elucidating the mechanisms of tumor aggression and therapeutic resistance. This significant research venture promises to alter the landscape of GBM treatment and improve the quality of life for countless patients battling this formidable disease.

As we continue to explore the depths of cancer biology, studies such as this will undoubtedly inspire further investigations into the cellular mechanisms at play and offer potential pathways to novel and more effective treatments.

Subject of Research: Glioblastoma multiforme glycosylation patterns

Article Title: Integrated proteomics and N-glycoproteomic characterization of glioblastoma multiform revealed N-glycosylation heterogeneities as well as alterations in sialyation and fucosylation.

Article References:

Hu, M., Xu, K., Yang, G. et al. Integrated proteomics and N-glycoproteomic characterization of glioblastoma multiform revealed N-glycosylation heterogeneities as well as alterations in sialyation and fucosylation.
Clin Proteom 22, 6 (2025). https://doi.org/10.1186/s12014-025-09525-9

Image Credits: AI Generated

DOI: 10.1186/s12014-025-09525-9

Keywords: glioblastoma multiforme, glycosylation, N-glycoproteomics, proteomics, cancer biology, therapeutic targeting, personalized medicine

The research taps into the ever-expanding field of marine biotechnology, which seeks to uncover natural compounds with therapeutic potential from oceanic biodiversity. Chaetoceros socialis, a unicellular photosynthetic diatom, is traditionally recognized for its ecological role rather than pharmacological properties. Yet, as biotechnology explores nature’s hidden pharmacopeia, compounds such as those extracted from this species emerge as intriguing candidates for targeting malignancies. By employing ethanol as a solvent to yield an extract rich in bioactive molecules, researchers have accessed a complex chemical repertoire capable of interfering with cancer cell homeostasis on multiple fronts.

Prostate cancer and glioblastoma represent two of the most challenging oncological burdens worldwide, both marked by aggressive cellular proliferation and notable resistance to conventional therapies. LNCap cells, derived from metastatic prostate carcinoma, and U-87 MG cells, a widely studied glioblastoma line, serve as robust in vitro models for evaluating anti-cancer efficacy. The study’s demonstration of cytotoxicity—marked decreases in viability—paired with clear indicators of apoptosis, underscores how this marine extract destabilizes survival signaling pathways that cancer cells rely upon to evade death.

At the heart of these pathways lies the AKT/PTEN axis, a crucial regulator of cell growth, metabolism, and survival. AKT kinase activity promotes oncogenic processes, while PTEN acts as a tumor suppressor by negatively regulating AKT. The ethanolic extract from Chaetoceros socialis was shown to modulate this axis, presumably tipping the balance toward PTEN-mediated suppression of AKT activity. Such modulation mitigates proliferative signals, effectively sensitizing cancer cells to apoptosis and halting unchecked growth.

Coupled with this, the mammalian target of rapamycin (mTOR) pathway, a downstream node in cellular signaling that governs protein synthesis and cellular metabolism, also exhibited altered activity. Aberrant mTOR activation is a hallmark of many cancers, including prostate and glioblastoma. By dampening mTOR signaling, the extract potentially disrupts the biosynthetic and anabolic machinery cancer cells harness to sustain rapid proliferation and survival in hostile microenvironments.

In the apoptosis regulatory landscape, the BAX/BCL2 ratio serves as a critical determinant of cell fate. BAX promotes apoptosis by permeabilizing mitochondrial membranes, facilitating cytochrome c release, whereas BCL2 functions antagonistically, inhibiting this process. The study’s findings reveal a shift in the BAX/BCL2 balance toward pro-apoptotic signaling after treatment with the marine extract. This suggests that the compounds contained within the extract instigate mitochondrial-mediated apoptotic mechanisms, reactivating death pathways that cancer cells often suppress to survive.

Further downstream, the activation of Caspase enzymes—the key executors of apoptosis—was noted, signifying that the extract’s pro-apoptotic triggers culminate in the dismantling of cancer cells. Caspase activation leads to systematic cleavage of cellular proteins and DNA fragmentation, hallmarks of irreversible apoptosis. Recognition of these effects in prostate and glioblastoma cell lines—cancers notorious for apoptosis evasion—underscores the therapeutic potential of the bioactive agents found in Chaetoceros socialis.

Importantly, this approach targets multiple regulatory nodes simultaneously, offering a multi-pronged attack that might overcome resistance mechanisms often limiting monotherapeutic interventions. Multi-target strategies are crucial given the genomic and phenotypic heterogeneity of tumors, wherein single-pathway targeting frequently leads to relapse. The extract’s polypharmacological profile could represent a natural prototype for combination treatments or even inspire synthetic analogs designed to emulate its efficacy with optimized pharmacokinetics.

From a broader perspective, these findings spotlight the ocean’s largely untapped reservoir of pharmacologically active substances. Marine microorganisms like diatoms have evolved complex biochemical arsenals to thrive in competitive aquatic ecosystems, often producing compounds with unique structural features not commonly found in terrestrial organisms. The therapeutic translation of these features could redefine cancer treatment paradigms, providing new weaponry against diseases that remain leading causes of mortality globally.

Moreover, the study exemplifies the power of integrating molecular biology techniques with natural product chemistry. By deciphering how an extract influences intracellular signaling circuits, researchers can precisely characterize mechanisms of action, enabling rational development of therapeutic candidates. This mechanistic clarity is vital in drug discovery to predict potential side effects, optimize dosage, and anticipate resistance profiles.

The therapeutic promise revealed here also raises critical questions for subsequent research. Elucidating the exact molecular constituents responsible for the observed bioactivity remains a priority, as crude extracts comprise myriad compounds whose individual and synergistic effects need deconvolution. Furthermore, in vivo validation within animal models will be essential to confirm efficacy, bioavailability, and safety, stepping stones before contemplating clinical trials.

Equally, understanding the pharmacodynamics and pharmacokinetics of the extract’s active components will influence dosing strategies and delivery mechanisms. Given the blood-brain barrier’s notorious restrictiveness, especially relevant for glioblastoma treatment, strategies enhancing central nervous system penetration are crucial if these findings are to translate clinically. Encapsulation technologies or structural modifications might serve to this end.

This line of investigation also intersects with personalized medicine. Tumor heterogeneity requires therapies tailored to specific molecular signatures, and the pathways modulated here—AKT/PTEN, mTOR, BAX/BCL2, Caspases—are variable across patients. Diagnostic tools capable of profiling tumors for these signaling aberrations would complement targeted use of marine-derived compounds, maximizing therapy responsiveness.

From a societal viewpoint, developments like these could reduce reliance on highly toxic chemotherapeutics, offering treatments with potentially fewer side effects due to their natural origin and multi-targeted nature. This aligns with the global agenda towards greener, more sustainable pharmaceutical innovation, underscoring the relevance of ecological conservation and biodiversity preservation.

As research accelerates in this domain, the integration of omics technologies—proteomics, transcriptomics, metabolomics—will deepen understanding of cellular responses to marine extracts, revealing off-target effects and novel molecular intersections. High-throughput screening combined with artificial intelligence-driven drug design could expedite the discovery process, translating marine biology insights into clinical success stories with unprecedented speed.

In conclusion, the presented study offers a compelling narrative of how a seemingly obscure marine microorganism—Chaetoceros socialis—harbors chemical agents with profound anti-cancer activity by rewiring key survival and apoptosis pathways in prostate and glioblastoma cells. This dual modulation of growth inhibition and programmed cell death mechanisms not only rejuvenates natural product research in oncology but also beckons a new era where marine ecosystems contribute front-line therapies against humanity’s deadliest diseases. As the scientific community continues to unravel nature’s complexities, the ocean may well harbor the cures of tomorrow.

Subject of Research: Cytotoxic and pro-apoptotic effects of Chaetoceros socialis ethanolic extract on prostate (LNCap) and glioblastoma (U-87 MG) cancer cells through modulation of the AKT/PTEN, mTOR, BAX/BCL2, and Caspase pathways.

Article Title: In vitro cytotoxic and pro-apoptotic effects of Chaetoceros socialis ethanolic extract on prostate (LNCap) and glioblastoma (U-87 MG) cells via modulation of AKT/PTEN, mTOR, BAX/BCL2, and Caspase pathways.

Article References:
Asoudeh-Fard, A., Jahromi, H.H., Zare, Z. et al. Med Oncol 42, 488 (2025). https://doi.org/10.1007/s12032-025-03034-3

Image Credits: AI Generated

This initiative stands as a testament to Pew’s commitment to strengthening scientific bonds between North and South America, providing rigorous mentorship and funding opportunities to extraordinary early-career investigators. The program’s structure not only supports groundbreaking research but also encourages returning fellows to reinvest their enhanced expertise into Latin America’s biomedical research infrastructure. In fact, close to seventy percent of previous participants have elected to establish their own laboratories back home, substantially enhancing the region’s capacity for innovation and scientific discovery.

The scientific inquiries undertaken by the 2025 fellows span a broad spectrum of biomedical challenges. Among the topics addressed is the exploration of how glioblastoma multiforme—the most aggressive and treatment-resistant type of brain tumor—develops metabolic adaptations to evade the cytotoxic effects of radiation therapy. Understanding these adaptive mechanisms at the molecular and metabolic level could revolutionize current therapeutic approaches and improve patient prognosis.

Equally compelling are investigations focusing on neural plasticity and repair. One fellow anticipates illuminating the molecular pathways through which the nervous system remodels itself post-injury, a critical area of study with profound implications for neuroregeneration and recovery following trauma. This research could uncover new avenues for developing regenerative therapies for neurodegenerative diseases and spinal cord injuries.

Another vital research avenue addressed by the fellows involves immunomodulation in the context of pain—a particularly understudied phenomenon during pregnancy. Chronic pain severely undermines quality of life, and the newly funded study aims to unravel how the maternal immune system modulates pain signaling, potentially identifying novel targets for therapeutic intervention that do not compromise fetal health.

Zika virus pathogenesis is a recurrent theme among many fellows, with two projects dissecting how this flavivirus disrupts normal brain development during pregnancy. One project focuses on the second trimester cerebral cortex’s development, elucidating viral interference with neuronal progenitor cells and cortical layering. Another complementary study delves into the genetic regulatory networks essential for brain development, probing how Zika virus infection causes neurodevelopmental disorders by perturbing these intricate networks.

In the realm of metabolic biochemistry, attention is directed towards selenium metabolism, an essential micronutrient implicated in antioxidant defense and thyroid function. Exploring the molecular pathways governing selenium utilization in cancerous cells could reveal metabolic vulnerabilities that might be exploited for targeted cancer therapies.

In cardiovascular developmental biology, one fellow investigates the electrical properties of cardiac tissue, particularly membrane potential dynamics. This research scrutinizes how ionic distributions across cardiomyocyte membranes orchestrate morphogenetic processes during heart development, offering potential insights into congenital cardiac defects.

Additional studies include evaluating cellular adaptations to hypoxia in the brain, which are critical for understanding stroke resilience and neurodegenerative conditions. Furthermore, investigations are underway into the mechanisms by which bacterial small RNAs regulate iron homeostasis, a process fundamental to bacterial survival and pathogenicity, and with implications for antibiotic resistance.

The mentorship guiding these investigations includes luminaries such as Dr. Sarah McMenamin at Boston College, Dr. Christian Mosimann at the University of Colorado School of Medicine, and Dr. James Olzmann at the University of California, Berkeley. Many mentors bring rich experience as previous Pew scholars themselves, reinforcing a vibrant academic lineage that nurtures cutting-edge science.

The Pew Charitable Trusts underscores that this assembly of fellows embodies the essence of scientific curiosity and transformative potential, promising significant contributions to biomedical sciences globally. These young researchers not only push the boundaries of their respective fields but also strengthen the scientific fabric linking Latin America with global innovation hubs, a synergy critical for addressing complex health challenges of the 21st century.

Backed by generous funding and exceptional mentorship, this new wave of Pew Latin American Fellows is poised to make lasting impacts in cancer biology, neurodevelopment, immunology, infectious disease, and beyond. Their research will illuminate fundamental biological processes while fostering an international culture of scientific excellence and collaboration.

—

Subject of Research: Biomedical sciences; research on brain tumors, nervous system repair, immunology in pregnancy, viral impacts on neurodevelopment, selenium metabolism, cardiac development, hypoxia adaptation, bacterial iron regulation.

Article Title: Pew Charitable Trusts Announces 2025 Class of Latin American Biomedical Science Fellows

News Publication Date: 2025

Web References: (Not provided)

References: (Not provided)

Image Credits: (Not provided)

Keywords: Biomedical research funding, Biochemistry, Cell biology, Genetics, Developmental biology, Neuroscience, Cancer

Glioblastoma multiforme (GBM) stands as one of the most lethal and treatment-resistant forms of brain cancer, characterized by rapid proliferation and invasive behavior. Standard therapeutic regimens involving surgery, radiation, and chemotherapy have yielded limited improvements in patient outcomes. Emerging evidence points towards metabolic reprogramming within glioma cells as a driver of malignancy, with lipid metabolism—and particularly cholesterol homeostasis—emerging as critical facets. Cholesterol is indispensable for cell membrane synthesis, signal transduction, and the maintenance of membrane microdomains, all vital facets for cancer cell proliferation.

The latest research employed sophisticated molecular biology techniques including RNA sequencing to examine gene expression changes triggered by exogenous cholesterol supplementation in glioma cell lines. The results illuminated a pronounced upregulation of APOL4 expression following cholesterol treatment. This observation prompted further investigation into APOL4’s role using clinical data from the Chinese Glioma Genome Atlas (CGGA), revealing elevated APOL4 levels in glioblastoma patient samples relative to normal tissue controls.

Functionally characterizing APOL4, the study utilized CRISPR-Cas9 gene editing to knock down APOL4 expression in glioblastoma cell cultures. The silencing of APOL4 led to a striking reduction in cell proliferation, underscoring its oncogenic potential. Complementary wound healing assays demonstrated impaired migratory capacity in APOL4-depleted cells, suggesting a critical role in tumor invasiveness. Immunofluorescence investigations further mapped the subcellular localization of APOL4 to late endosomes and lysosomes, intracellular compartments pivotal for cholesterol trafficking.

These vesicular structures facilitate the transport and distribution of cholesterol within the cytoplasm, enabling proper membrane synthesis and energy regulation essential for the heightened metabolic demands of tumor cells. By mediating cholesterol trafficking, APOL4 appears to promote the availability of cholesterol pools necessary for glioblastoma cell growth and survival. This molecular mechanism provides a potential explanation for how aberrant lipid metabolism contributes to tumor aggressiveness.

To verify the impact of APOL4 on tumor progression in a living organism, researchers developed xenograft mouse models implanted with APOL4-deficient glioblastoma cells. Compared to controls, the APOL4-depleted tumors exhibited significantly attenuated growth rates, confirming in vivo the protein’s pivotal role in glioma proliferation and malignancy. These compelling data not only validate APOL4 as a novel biomarker but also as a plausible therapeutic target.

The implications of this study extend beyond basic science and clinical prognostication, highlighting the therapeutic promise of disrupting intracellular cholesterol trafficking in glioblastoma management. Existing cholesterol-targeting agents, including statins and emerging lipid metabolism inhibitors, may be repurposed or optimized to exploit this vulnerability in tumor cells. Moreover, APOL4-specific interventions could complement current treatment modalities by crippling the metabolic flexibility that glioma cells rely upon.

Interestingly, while apolipoproteins have conventionally been studied in the context of systemic lipid transport and cardiovascular health, their intracellular functions within cancer cells have remained largely enigmatic. This research pioneers the characterization of APOL4’s intracellular trafficking role, hinting at a broader paradigm where members of the apolipoprotein L family regulate tumor cell metabolism and survival in the microenvironment.

The study’s bioinformatics analyses reinforce the clinical relevance of APOL4, with data revealing a correlation between heightened APOL4 expression and poor prognosis in glioblastoma patients. This suggests that monitoring APOL4 levels could serve as a diagnostic adjunct or predictor of treatment response, aligning with the precision medicine ethos driving contemporary oncology.

From a mechanistic perspective, the localization of APOL4 to the late endosome-lysosome system integrates with known pathways of cholesterol egress, including the Niemann-Pick type C (NPC) protein family that governs cholesterol trafficking from lysosomal compartments. Interactions or functional intersections between APOL4 and these pathways warrant deeper exploration to fully elucidate therapeutic windows.

Given the complexity of glioblastoma metabolism, targeting APOL4 may help overcome resistance phenotypes caused by compensatory metabolic pathways. Combining APOL4 inhibition with treatments that disrupt other metabolic axes, such as glucose metabolism or fatty acid oxidation, might yield synergistic anti-cancer effects and suppress tumor recurrence.

The discovery of APOL4’s role in glioma thereby represents a significant stride towards decoding the metabolic underpinnings of brain tumor malignancy. Future investigations are poised to dissect the structural biology of APOL4, delineate its regulatory networks, and develop small molecule inhibitors or antibody-based therapeutics to selectively impair its function.

In conclusion, this research not only delineates a novel molecular mechanism underpinning glioblastoma growth through APOL4-mediated cholesterol trafficking but also amplifies the clarion call to integrate metabolic targeting in cancer therapy paradigms. As lipid metabolism reemerges as a frontier in oncology research, APOL4 stands at the vanguard as both a biomarker and a beacon for innovative treatment strategies, offering hope in the confrontation with one of medicine’s most formidable adversaries.

Subject of Research: Glioblastoma, cholesterol metabolism, intracellular cholesterol trafficking, APOL4 function, tumor growth mechanisms.

Article Title: APOL4-mediated intracellular cholesterol trafficking is essential for glioblastoma cell growth.

Article References:
Zhang, M., Yang, T. & Qian, Y. APOL4-mediated intracellular cholesterol trafficking is essential for glioblastoma cell growth. BMC Cancer 25, 906 (2025). https://doi.org/10.1186/s12885-025-14316-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14316-4

The study, published in BioMedical Engineering OnLine, represents a significant stride in cancer modeling by moving away from traditional two-dimensional cultures toward a more physiologically relevant 3D model. The researchers synthesized and characterized three distinct hydrogel formulations to identify the optimal matrix for cultivating GBM cells in a way that mirrors their natural behavior within the brain. Hydrogels, due to their high water content and tunable mechanical properties, are emerging as premier scaffolds for 3D cell cultures, capable of mimicking the extracellular matrix (ECM) stiffness and biochemical cues critical for maintaining tumor cell phenotype and function.

To determine which hydrogel formulation best supported GBM cell growth, the team utilized an array of sophisticated techniques. Rheological measurements provided detailed insights into the mechanical stiffness and viscoelastic properties of each hydrogel, essential features that influence cell behavior in three-dimensional space. Fourier transform infrared spectroscopy (FT-IR) allowed for precise chemical characterization, confirming the successful combination of gelatin and sodium alginate polymers. Additionally, scanning electron microscopy (SEM) helped visualize the hydrogel’s porous architecture, crucial for nutrient diffusion and waste removal in long-term cell cultures.

Among the three hydrogels tested, the formulation containing 5% weight/weight gelatin combined with 5% sodium alginate emerged superior. This specific composition not only exhibited ideal rheological properties that simulate the brain’s soft tissue environment but also supported the highest viability of GBM cells over extended culture periods. Gelatin, rich in bioactive motifs such as Arg-Gly-Asp (RGD) sequences, facilitates cell adhesion and proliferation, while the alginate component enhances structural integrity. This hybrid scaffold successfully maintained the three-dimensional organization of tumor spheroids, a critical advance beyond traditional monolayer cultures.

With the optimal hydrogel platform established, the researchers turned their attention to probing the role of CD73, an extracellular enzyme known to generate adenosine, which promotes immunosuppression and tumor progression. Previous studies have hinted at CD73’s involvement in GBM pathogenesis, but in vitro models capable of reflecting these dynamics were lacking. Using their 3D culture model, the team exposed GBM cell spheroids to a selective CD73 inhibitor to evaluate therapeutic responsiveness.

The results were compelling: CD73 inhibition led to a pronounced reduction in GBM cell proliferation within the hydrogel model. Furthermore, molecular analysis via real-time PCR demonstrated significant downregulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1-alpha (HIF1-α), two critical mediators of angiogenesis and hypoxic adaption in tumors. These changes suggest that blocking CD73 disrupts the tumor’s capacity to sustain its microenvironment and promotes vulnerability to treatment.

This 3D culture system marks a paradigm shift in GBM research by enabling the study of tumor biology and drug responses in conditions that faithfully recapitulate in vivo physiology. Traditional 2D cultures fail to reproduce the cellular heterogeneity, spatial architecture, and microenvironmental pressures characteristic of brain tumors. Consequently, drug responses observed in 2D often lack translational relevance. The hydrogel-based model’s success underscores the importance of biomechanical and biochemical cues in cancer modeling, improving the predictability of preclinical findings.

Importantly, the study’s hydrogel scaffold can be adapted to incorporate additional ECM components or to co-culture GBM cells with stromal and immune cells, opening avenues for even more complex and realistic tumor models. This versatility is critical in the context of GBM, where interactions between cancer cells and the surrounding stroma, including immune cells, play vital roles in tumor progression and resistance to therapy.

Moreover, the findings highlight CD73 as a promising therapeutic target in GBM treatment regimens. CD73’s enzymatic activity generates extracellular adenosine, which suppresses anti-tumor immune responses and fosters pro-tumorigenic signaling pathways. The observed decrease in VEGF and HIF1-α expression following CD73 inhibition suggests that this approach may impair tumor angiogenesis and adaptation to hypoxic stress, both hallmarks of aggressive GBM. These molecular changes provide mechanistic insights and emphasize the potential benefit of combining CD73 inhibitors with current standards of care, such as radiotherapy and temozolomide chemotherapy.

On a broader scale, this research exemplifies the growing intersection between bioengineering and cancer biology. Material science innovations like engineered hydrogels are vital tools enabling the recreation of complex tumor microenvironments in vitro. By combining material characterization techniques (rheology, FT-IR, SEM) with molecular and cellular assays, the study offers a holistic approach that bridges the gap between laboratory models and clinical realities, fostering the translation of bench discoveries into tangible cancer therapies.

The implications of this work extend beyond glioblastoma. Hydrogel-based 3D cultures could be customized for other solid tumors where microenvironmental factors dictate therapeutic sensitivities. Personalized medicine applications also become feasible, where patient-derived tumor cells can be cultured in hydrogels that simulate their native environment, allowing rapid screening of therapeutic compounds and personalized treatment strategies.

In sum, the development of this hydrogel-based 3D culture system is a critical advance in GBM research, providing a robust and versatile platform that captures tumor complexity and facilitates the study of targeted therapies such as CD73 inhibitors. The combination of precise material engineering and rigorous biological validation heralds a new era where cancer treatment development is informed by more physiologically relevant models, promising improved outcomes for patients with this devastating disease.

As ongoing research continues to refine and expand upon these findings, it is anticipated that hydrogel-based 3D culture systems will become foundational in preclinical oncology research, accelerating drug discovery pipelines and enhancing the predictive power of experimental cancer models. The study offers renewed hope that integrating bioengineering and molecular targeting can unlock new strategies to overcome the formidable barriers in glioblastoma therapy.

Subject of Research: Glioblastoma multiforme cell culture models and therapeutic response to CD73 inhibition using hydrogel-based 3D systems.

Article Title: Development of a hydrogel-based three-dimensional (3D) glioblastoma cell lines culture as a model system for CD73 inhibitor response study.

Article References:
Bahraminasab, M., Asgharzade, S., Doostmohamadi, A. et al. Development of a hydrogel-based three-dimensional (3D) glioblastoma cell lines culture as a model system for CD73 inhibitor response study. BioMed Eng OnLine 23, 127 (2024). https://doi.org/10.1186/s12938-024-01320-1

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12938-024-01320-1